January 2019. Last week saw the annual J.P. Morgan Healthcare Conference held in San Francisco. Venture Valuation and Biotechgate was represented by CEO, Patrik Frei and Senior Business Development Executive Ray Carroll providing their insights into the industry announcements. It was again a busy week in San Francisco kicking off the Bio year 2019 where … Continue reading J.P. Morgan Healthcare Conference Round-up by Venture Valuation / Biotechgate
Invented by Prof. Hiroshi Kobayashi, Department of Mechanical Engineering, Tokyo University of Science, the Muscle Suit® is becoming an indispensable device for the elderly care services as well as many other heavy lifting tasks. Venture Valuation (VV) interviewed Takashi Furukawa, CEO. Read the interview Would you like to be notified about new reports and other … Continue reading Interviews with leading Life Sciences companies: Innophys Co.
Zurich / Montréal, November 26, 2018 As part of the ongoing commitment of Montréal InVivo to promote the economic development and growth of the life sciences and health technologies (LSHT) sector in Québec, Biotechgate, a company owned by Venture Valuation, and Montréal InVivo, the LSHT industrial cluster of the Montreal metropolitan area, announce a partnership … Continue reading Launch of a Directory of Life Sciences and Health Technologies companies with an exclusive database in Québec
RESI Conference, Boston, Sep 2018, 36 pages Deal and Product Valuations Deal and Product Valuations
Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector. Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years. Analysing this data from … Continue reading Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech
Biotech Investment Showcase, London, May 2018, 22 pages How to value a Biotech Start-up company
Current transfusion medicine entirely relies on donated blood. Megakaryon will change the transfusion practices by supplying safe and cost-saving platelets produced in vitro. Mass production in Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder. Read the interview
